Drug intelligence / Profile preview

BTV100

Development stage: Unknown
Lead developer: BioTheraVision
Administration: Ophthalmic

Overview

BTV100 is an investigational ophthalmic drug being developed by BioTheraVision for the treatment of dry eye disease (DED), also known as dry eye syndromes or keratoconjunctivitis sicca. The drug is currently in Phase 2 clinical trials in Australia and Taiwan. The precise mechanism of action for BTV100 has not been disclosed. It is administered via the ophthalmic route and, as of now, has not received regulatory approval in any country.

Beyond the preview

Go deeper on BTV100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTV100.

Explore the full profile